Sensus Healthcare (NASDAQ:SRTS) Director Buys $34,741.50 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 10,925 shares of the stock in a transaction on Thursday, August 27th. The shares were acquired at an average cost of $3.18 per share, for a total transaction of $34,741.50. Following the completion of the transaction, the director directly owned 229,943 shares in the company, valued at $731,218.74. The trade was a 4.99% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Eric Sachetta also recently made the following trade(s):

• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $3.52 on Monday. Sensus Healthcare, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $5.49. The firm has a 50-day simple moving average of $3.05 and a 200-day simple moving average of $3.51. The company has a market capitalization of $57.94 million, a price-to-earnings ratio of -3.74 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare during the 2nd quarter valued at approximately $49,000. XTX Topco Ltd acquired a new stake in Sensus Healthcare in the fourth quarter valued at $77,000. Jane Street Group LLC purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $79,000. Ingalls & Snyder LLC acquired a new position in shares of Sensus Healthcare during the 4th quarter worth $219,000. Finally, BlackRock Inc. acquired a new position in shares of Sensus Healthcare during the 2nd quarter worth $252,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings lowered shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.83.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.